Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.9K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Immediate Impact of Infarct Size on the Systemic Inflammatory Response: IL-6 as Central Mediator Identified through Biomarker and Proteomic Profiling.

Journal of cardiovascular translational research·2026
Same author

Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis.

JAMA cardiology·2026
Same author

Natural history of thyroid function in ageing: an individual participant data analysis of 137 488 participants from 31 prospective cohort studies.

The lancet. Diabetes & endocrinology·2026
Same author

Residual HIV viremia strongly increases cardiovascular disease incidence independent of classical risk factors.

The Journal of infection·2026
Same author

Effect of 2 Weeks of Time-Restricted Eating on Innate Immunity and Systemic Inflammation in Patients With a History of Myocardial Infarction: A Randomized-Controlled Crossover Study.

Journal of the American Heart Association·2026
Same author

Urinary Proteomics as a Noninvasive Readout of Obesity-associated Inflammation.

Journal of the Endocrine Society·2026
Same journal

[Improving mobility in painful osteoarthritis].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[The effectiveness and costs of the Back At work After Surgery (BAAS) work-integrated care pathway on return to work for patients receiving knee arthroplasty].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[The rise of genetic therapies: urgent moral and societal questions].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[A man with a wound on his elbow].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[Employment of safety net enclosures].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[The power of a neurodiversity perspective; demedicalizing mental health support].

Nederlands tijdschrift voor geneeskunde·2026
See all related articles

Related Experiment Video

Updated: May 3, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

14.4K

[Clopidogrel cannot yet be exclusively for smokers].

Niels P Riksen1

  • 1Universitair Medisch Centrum St Radboud, afd. Interne Geneeskunde en afd. Farmacologie-Toxicologie, Nijmegen.

Nederlands Tijdschrift Voor Geneeskunde
|February 13, 2014
PubMed
Summary
This summary is machine-generated.

Smoking may enhance the effectiveness of clopidogrel, a P2Y12 receptor antagonist, in preventing cardiovascular events. Further research is needed to confirm this effect and assess bleeding risks in smokers.

More Related Videos

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
06:07

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

6.7K
A Protocol for Detecting and Scavenging Gas-phase Free Radicals in Mainstream Cigarette Smoke
09:23

A Protocol for Detecting and Scavenging Gas-phase Free Radicals in Mainstream Cigarette Smoke

Published on: January 2, 2012

19.6K

Related Experiment Videos

Last Updated: May 3, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

14.4K
Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
06:07

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

6.7K
A Protocol for Detecting and Scavenging Gas-phase Free Radicals in Mainstream Cigarette Smoke
09:23

A Protocol for Detecting and Scavenging Gas-phase Free Radicals in Mainstream Cigarette Smoke

Published on: January 2, 2012

19.6K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard for acute coronary syndromes and stenting.
  • Recent meta-analyses suggest enhanced clopidogrel efficacy in smokers.

Purpose of the Study:

  • To explore the potential impact of smoking on clopidogrel's efficacy and safety.
  • To investigate the mechanism behind potentially increased clopidogrel effectiveness in smokers.

Main Methods:

  • Review of existing meta-analyses on clopidogrel efficacy in smokers versus non-smokers.
  • Hypothesized mechanism involving smoking-induced cytochrome P450 1A2 activity.

Main Results:

  • Meta-analyses indicate a more pronounced reduction in cardiovascular events with clopidogrel among smokers.
  • Smoking may accelerate the conversion of clopidogrel to its active metabolite via CYP1A2 induction.

Conclusions:

  • Observed enhanced clopidogrel efficacy in smokers warrants further investigation.
  • Prospective trials are necessary to validate these findings and evaluate bleeding risks associated with smoking and clopidogrel therapy.